TICKERNERD
Menu
TTRXTTRXHealthcare · Biotechnology

TTRX Stock Forecast: Turn Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 3 Aug 2026
$8.84
+5.74% on the day

The 1 Wall Street analysts covering Turn Therapeutics, Inc. hold a median 12-month price target of $26 — +194.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 15 of 100 as at 1 Aug 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$249.0M
Ticker Nerd rank
15 / 100
Median analyst target
$26
Analysts covering
1
Total return, dividends reinvested
1W
+13.6%
1M
+24.2%
YTD
+124.4%
From high
−13.2%
From low
+226.2%
$3
$10
Range since 8 Oct 2025, adjusted closes · the dot is the last close
Ticker Nerd rank

TTRX stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Turn Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 1 Aug 2026
15 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Value
80
Size
65
Revisions
58
Growth
25
Quality
20
Accruals
16
Momentum
9
Issuance
9
Volatility
3

Value (80): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.

Volatility (3): The share price moves around a lot.

The rank is the raw material. Whether the rules would actually own Turn Therapeutics, Inc. — and when they’d sell — is the membership.

Wall Street

TTRX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on TTRX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, since 8 Oct 2025Adjusted close, US dollars
$0$5$10$15$20$25Jan 26Apr 26Jul 26TTRXHigh $26Median $26Low $26

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says1 analysts
1 Buy0 Hold0 Sell
Low $26Median $26High $26

The green dot is the last close — the median target sits +194.1% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
24 Mar 2026D. Boral CapitalMaintainsBuy$8.00
24 Mar 2026D. Boral CapitalMaintainsBuy—
20 Jan 2026D. Boral CapitalMaintainsBuy—
29 Dec 2025D. Boral CapitalInitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Estimates

TTRX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
0
Fundamentals

Turn Therapeutics, Inc. (TTRX) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−69.7×

Cheaper than 99% of US stocks

Price / sales
—
Price / book
40.8×

Cheaper than 3% of US stocks

EV / EBITDA
−31.9×

Cheaper than 92% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 35% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−129.2%

Higher than 10% of US stocks

Return on assets
—
Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

TTRX vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
TTRXTurn Therapeutics, Inc.$249.0M
15
IFRXInflaRx NV$250.4M
14
ELDNEledon Pharmaceuticals, Inc.$253.8M
30
ALXOALX Oncology Holdings, Inc.$254.5M
63
AVXLAnavex Life Sciences Corp.$254.8M
20
SRZNSurrozen, Inc.$255.1M
66
MGNXMacroGenics, Inc.$234.5M
78
Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. TTRX appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

News

Latest TTRX news & analysis

Turn Therapeutics to Ring the Nasdaq Closing Bell on Monday, August 10, 2026

Business Wire · 28 July 2026positive

Turn Therapeutics announced that CEO Bradley Burnam and members of the management team will ring the Nasdaq Closing Bell on August 10, 2026, at Nasdaq's invitation to mark the company's progress to date.

Why it matters — The Nasdaq's invitation for Turn Therapeutics to ring the closing bell signals recognition of the company's achievements and milestones as a publicly traded clinical-stage biotechnology firm.

FAQ

Frequently asked questions about TTRX stock

What is the TTRX stock price forecast for 2026-2027?

The 1 Wall Street analysts covering Turn Therapeutics, Inc. have a median 12-month price target of $26, with estimates ranging from $26 to $26. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is TTRX stock a buy right now?

Of the 1 analysts covering Turn Therapeutics, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Turn Therapeutics, Inc. 15 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank TTRX?

As at 1 Aug 2026, Turn Therapeutics, Inc. ranks 15 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (80 of 100).

Will TTRX stock go up?

No one can know that. What the data says: the median 12-month target from 1 analysts implies +194.1% from the last close, and Ticker Nerd's factor model ranks Turn Therapeutics, Inc. 15 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the TTRX stock forecast for 2030?

No analyst covering Turn Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for TTRX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $26 to $26 over the next 12 months.

What does Turn Therapeutics, Inc. do?

Turn Therapeutics Inc. is a biotechnology and pharmaceuticals company dedicated to developing innovative drugs and medical devices for dermatological, wound care, and infectious disease management.

What is the latest news on TTRX?

The most recent item we track (Business Wire, 28 July 2026): "Turn Therapeutics to Ring the Nasdaq Closing Bell on Monday, August 10, 2026". Turn Therapeutics announced that CEO Bradley Burnam and members of the management team will ring the Nasdaq Closing Bell on August 10, 2026, at Nasdaq's invitation to mark the company's progress to date.

Company

About Turn Therapeutics, Inc.

Turn Therapeutics Inc. is a biotechnology and pharmaceuticals company dedicated to developing innovative drugs and medical devices for dermatological, wound care, and infectious disease management. Central to its approach is the proprietary PermaFusion drug delivery platform, which enables the stable suspension of water-soluble active pharmaceutical ingredients within oil-based carriers, enhancing bioavailability and reducing the risk of adverse effects tied to lower active ingredient dosages. Founded in 2015 and headquartered in Westlake Village, California, the company focuses primarily on diseases of the skin, nails, and eyes, with significant research and clinical programs addressing moderate to severe eczema and onychomycosis (nail fungus). Turn Therapeutics' technologies, including its flagship Hexagen formula, have achieved multiple FDA medical device clearances for advanced wound and dermatitis care, substantiating their safety and efficacy. The company’s mission centers on advancing patient-centric therapies that minimize invasiveness and antibiotic resistance, respond to unmet medical needs, and continuously redefine standards of care in the healthcare and biotechnology sectors.

CEO Mr. Bradley E. Burnam · 2 employees · United States · https://turntherapeutics.com